Traws Pharma (ONTX) Stock Forecast, Price Target & Predictions
ONTX Stock Forecast
Traws Pharma stock forecast is as follows: a rating consensus of 'Buy', based on 2 wall street analysts offering a 1-year stock forecast.
ONTX Analyst Ratings
Analyst Ratings Upgrades/Downgrades
Date | Company | Previous Rating | New Rating | Rating Change |
---|---|---|---|---|
Apr 21, 2023 | H.C. Wainwright | - | Buy | Upgrade |
May 18, 2021 | Guggenheim | - | Buy | Initialise |
Traws Pharma Financial Forecast
Traws Pharma Revenue Forecast
Dec 24 | Oct 24 | Jul 24 | Mar 24 | Dec 23 | Oct 23 | Jul 23 | Mar 23 | Dec 22 | Oct 22 | Jul 22 | Mar 22 | Dec 21 | Oct 21 | Jul 21 | Mar 21 | Dec 20 | Oct 20 | Jul 20 | Mar 20 | Dec 19 | Oct 19 | Jul 19 | Mar 19 | Mar 18 | Mar 17 | Mar 16 | Mar 15 | Mar 14 | Oct 13 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | - | - | - | - | - | - | - | $56.00K | $56.00K | - | - | $56.00K | $-58.00K | - | - | $56.00K | $57.00K | - | - | $52.00K | $30.00K | - | - | $68.00K | $564.00K | $210.00K | $1.47M | $114.00K | $447.00K | - |
Avg Forecast | $2.72M | $60.00K | $60.00K | $60.00K | $65.33K | $69.25K | $69.25K | $79.00K | $80.00K | $73.67K | $73.00K | $79.00K | $59.50K | $53.33K | $20.00K | $60.00K | $45.00K | $1.39M | $173.00K | $88.00K | $66.50K | $803.67K | $494.75K | $85.00K | $647.84K | $171.53K | $1.03M | $121.58K | $381.45K | $751.52K |
High Forecast | $2.72M | $60.00K | $60.00K | $60.00K | $65.33K | $69.38K | $69.25K | $79.00K | $80.00K | $73.67K | $73.00K | $79.00K | $59.50K | $53.33K | $20.00K | $60.00K | $45.00K | $1.39M | $173.00K | $88.00K | $66.50K | $803.67K | $494.75K | $85.00K | $777.41K | $205.83K | $1.24M | $145.89K | $457.74K | $901.82K |
Low Forecast | $2.72M | $60.00K | $60.00K | $60.00K | $65.33K | $69.13K | $69.25K | $79.00K | $80.00K | $73.67K | $73.00K | $79.00K | $59.50K | $53.33K | $20.00K | $60.00K | $45.00K | $1.39M | $173.00K | $88.00K | $66.50K | $803.67K | $494.75K | $85.00K | $518.27K | $137.22K | $827.55K | $97.26K | $305.16K | $601.21K |
# Analysts | 1 | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 4 | 7 | 4 | 4 | 3 | 5 | 3 | 3 | 9 | 9 | 13 | 8 | 10 | 13 |
Surprise % | - | - | - | - | - | - | - | 0.71% | 0.70% | - | - | 0.71% | -0.97% | - | - | 0.93% | 1.27% | - | - | 0.59% | 0.45% | - | - | 0.80% | 0.87% | 1.22% | 1.42% | 0.94% | 1.17% | - |
Traws Pharma EBITDA Forecast
Dec 24 | Oct 24 | Jul 24 | Mar 24 | Dec 23 | Oct 23 | Jul 23 | Mar 23 | Dec 22 | Oct 22 | Jul 22 | Mar 22 | Dec 21 | Oct 21 | Jul 21 | Mar 21 | Dec 20 | Oct 20 | Jul 20 | Mar 20 | Dec 19 | Oct 19 | Jul 19 | Mar 19 | Mar 18 | Mar 17 | Mar 16 | Mar 15 | Mar 14 | Oct 13 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
# Analysts | 1 | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 4 | 7 | 4 | 4 | 3 | 5 | 3 | 3 | 9 | 9 | 13 | 8 | 10 | 13 |
EBITDA | - | - | - | - | - | - | - | $-6.13M | $-5.73M | - | - | $-4.13M | $-3.76M | - | - | $-4.71M | $-2.42K | - | - | $-5.09M | $-5.74M | - | - | $-7.59M | $-5.07M | $-8.32M | $-7.22M | $-12.27M | $-18.54M | - |
Avg Forecast | $-2.72M | $-60.00K | $-60.00K | $-60.00K | $-65.33K | $-69.25K | $-69.25K | $-79.00K | $-80.00K | $-73.67K | $-73.00K | $-3.90M | $-59.50K | $-53.33K | $-20.00K | $-6.28M | $-45.00K | $-1.39M | $-173.00K | $-6.41M | $-66.50K | $-803.67K | $-494.75K | $-5.68M | $-5.76M | $-6.45M | $-4.60M | $-13.44M | $-15.21M | $-10.28M |
High Forecast | $-2.72M | $-60.00K | $-60.00K | $-60.00K | $-65.33K | $-69.13K | $-69.25K | $-79.00K | $-80.00K | $-73.67K | $-73.00K | $-3.12M | $-59.50K | $-53.33K | $-20.00K | $-5.03M | $-45.00K | $-1.39M | $-173.00K | $-5.13M | $-66.50K | $-803.67K | $-494.75K | $-4.54M | $-4.61M | $-5.16M | $-3.68M | $-10.75M | $-12.17M | $-8.23M |
Low Forecast | $-2.72M | $-60.00K | $-60.00K | $-60.00K | $-65.33K | $-69.38K | $-69.25K | $-79.00K | $-80.00K | $-73.67K | $-73.00K | $-4.68M | $-59.50K | $-53.33K | $-20.00K | $-7.54M | $-45.00K | $-1.39M | $-173.00K | $-7.69M | $-66.50K | $-803.67K | $-494.75K | $-6.81M | $-6.91M | $-7.74M | $-5.51M | $-16.13M | $-18.25M | $-12.34M |
Surprise % | - | - | - | - | - | - | - | 77.65% | 71.67% | - | - | 1.06% | 63.19% | - | - | 0.75% | 0.05% | - | - | 0.79% | 86.38% | - | - | 1.34% | 0.88% | 1.29% | 1.57% | 0.91% | 1.22% | - |
Traws Pharma Net Income Forecast
Dec 24 | Oct 24 | Jul 24 | Mar 24 | Dec 23 | Oct 23 | Jul 23 | Mar 23 | Dec 22 | Oct 22 | Jul 22 | Mar 22 | Dec 21 | Oct 21 | Jul 21 | Mar 21 | Dec 20 | Oct 20 | Jul 20 | Mar 20 | Dec 19 | Oct 19 | Jul 19 | Mar 19 | Mar 18 | Mar 17 | Mar 16 | Mar 15 | Mar 14 | Oct 13 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
# Analysts | 1 | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 4 | 7 | 4 | 4 | 3 | 5 | 3 | 3 | 9 | 9 | 13 | 8 | 10 | 13 |
Net Income | - | - | - | - | - | - | - | $-5.41M | $-5.00M | - | - | $-4.11M | $-3.76M | - | - | $-4.71M | $-6.43K | - | - | $-5.09M | $-5.75M | - | - | $-7.60M | $-5.09M | $-8.34M | $-7.24M | $-12.34M | $-18.68M | - |
Avg Forecast | $-5.16M | $-5.58M | $-5.26M | $-4.95M | $-5.33M | $-6.10M | $-6.58M | $-6.26M | $-5.84M | $-4.47M | $-4.16M | $-3.91M | $-5.68M | $-6.87M | $-6.00M | $-6.29M | $-10.52M | $-10.52M | $-9.47M | $-6.42M | $-22.10M | $-221.75M | $-277.77M | $-5.68M | $-5.78M | $-6.47M | $-4.61M | $-13.52M | $-15.32M | $-10.57M |
High Forecast | $-5.16M | $-5.58M | $-5.26M | $-4.95M | $-5.33M | $-6.10M | $-6.58M | $-6.26M | $-5.84M | $-4.47M | $-4.16M | $-3.12M | $-5.68M | $-6.87M | $-6.00M | $-5.03M | $-10.52M | $-10.52M | $-9.47M | $-5.13M | $-22.10M | $-221.75M | $-277.77M | $-4.55M | $-4.62M | $-5.18M | $-3.69M | $-10.81M | $-12.26M | $-8.45M |
Low Forecast | $-5.16M | $-5.58M | $-5.26M | $-4.95M | $-5.33M | $-6.10M | $-6.58M | $-6.26M | $-5.84M | $-4.47M | $-4.16M | $-4.69M | $-5.68M | $-6.87M | $-6.00M | $-7.54M | $-10.52M | $-10.52M | $-9.47M | $-7.70M | $-22.10M | $-221.75M | $-277.77M | $-6.82M | $-6.94M | $-7.76M | $-5.53M | $-16.22M | $-18.39M | $-12.68M |
Surprise % | - | - | - | - | - | - | - | 0.86% | 0.86% | - | - | 1.05% | 0.66% | - | - | 0.75% | 0.00% | - | - | 0.79% | 0.26% | - | - | 1.34% | 0.88% | 1.29% | 1.57% | 0.91% | 1.22% | - |
Traws Pharma SG&A Forecast
Dec 24 | Oct 24 | Jul 24 | Mar 24 | Dec 23 | Oct 23 | Jul 23 | Mar 23 | Dec 22 | Oct 22 | Jul 22 | Mar 22 | Dec 21 | Oct 21 | Jul 21 | Mar 21 | Dec 20 | Oct 20 | Jul 20 | Mar 20 | Dec 19 | Oct 19 | Jul 19 | Mar 19 | Mar 18 | Mar 17 | Mar 16 | Mar 15 | Mar 14 | Oct 13 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
# Analysts | 1 | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 4 | 7 | 4 | 4 | 3 | 5 | 3 | 3 | 9 | 9 | 13 | 8 | 10 | 13 |
SG&A | - | - | - | - | - | - | - | $2.11M | $2.02M | - | - | $2.19M | $2.07M | - | - | $2.22M | $1.78M | - | - | $1.81M | $1.71M | - | - | $3.23M | $1.89M | $2.12M | $3.17M | $2.96M | $4.93M | - |
Avg Forecast | $86.60M | $1.91M | $1.91M | $1.91M | $2.08M | $2.20M | $2.20M | $2.52M | $2.55M | $2.35M | $2.32M | $2.52M | $1.89M | $1.70M | $636.74K | $1.91M | $1.43M | $44.37M | $5.51M | $2.80M | $2.12M | $25.59M | $15.75M | $2.71M | $20.63M | $5.46M | $32.93M | $3.87M | $12.14M | $23.93M |
High Forecast | $86.60M | $1.91M | $1.91M | $1.91M | $2.08M | $2.21M | $2.20M | $2.52M | $2.55M | $2.35M | $2.32M | $2.52M | $1.89M | $1.70M | $636.74K | $1.91M | $1.43M | $44.37M | $5.51M | $2.80M | $2.12M | $25.59M | $15.75M | $2.71M | $24.75M | $6.55M | $39.52M | $4.64M | $14.57M | $28.71M |
Low Forecast | $86.60M | $1.91M | $1.91M | $1.91M | $2.08M | $2.20M | $2.20M | $2.52M | $2.55M | $2.35M | $2.32M | $2.52M | $1.89M | $1.70M | $636.74K | $1.91M | $1.43M | $44.37M | $5.51M | $2.80M | $2.12M | $25.59M | $15.75M | $2.71M | $16.50M | $4.37M | $26.35M | $3.10M | $9.72M | $19.14M |
Surprise % | - | - | - | - | - | - | - | 0.84% | 0.79% | - | - | 0.87% | 1.09% | - | - | 1.16% | 1.24% | - | - | 0.64% | 0.81% | - | - | 1.20% | 0.09% | 0.39% | 0.10% | 0.77% | 0.41% | - |
Traws Pharma EPS Forecast
Dec 24 | Oct 24 | Jul 24 | Mar 24 | Dec 23 | Oct 23 | Jul 23 | Mar 23 | Dec 22 | Oct 22 | Jul 22 | Mar 22 | Dec 21 | Oct 21 | Jul 21 | Mar 21 | Dec 20 | Oct 20 | Jul 20 | Mar 20 | Dec 19 | Oct 19 | Jul 19 | Mar 19 | Mar 18 | Mar 17 | Mar 16 | Mar 15 | Mar 14 | Oct 13 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
# Analysts | 1 | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 4 | 7 | 4 | 4 | 3 | 5 | 3 | 3 | 9 | 9 | 13 | 8 | 10 | 13 |
EPS | - | - | - | - | - | - | - | $-0.26 | $-0.24 | - | - | $-0.20 | $-0.24 | - | - | $-0.30 | $-0.00 | - | - | $-0.45 | $-14.04 | - | - | $-19.35 | $-76.50 | $-276.75 | $-607.49 | $-1.28K | $-1.96K | - |
Avg Forecast | $-0.24 | $-0.27 | $-0.25 | $-0.23 | $-0.25 | $-0.29 | $-0.31 | $-0.30 | $-0.28 | $-0.21 | $-0.20 | $-0.19 | $-0.27 | $-0.33 | $-0.28 | $-0.45 | $-0.50 | $-0.50 | $-0.45 | $-0.82 | $-1.05 | $-10.54 | $-13.20 | $-15.53 | $-6.70 | $-11.69 | $-1.21 | $-6.90 | $-90.74 | $-50.40 |
High Forecast | $-0.24 | $-0.27 | $-0.25 | $-0.23 | $-0.25 | $-0.29 | $-0.31 | $-0.30 | $-0.28 | $-0.21 | $-0.20 | $-0.19 | $-0.27 | $-0.33 | $-0.28 | $-0.45 | $-0.50 | $-0.50 | $-0.45 | $-0.82 | $-1.05 | $-10.54 | $-13.20 | $-15.53 | $-5.36 | $-9.35 | $-0.97 | $-5.52 | $-72.59 | $-40.32 |
Low Forecast | $-0.24 | $-0.27 | $-0.25 | $-0.23 | $-0.25 | $-0.29 | $-0.31 | $-0.30 | $-0.28 | $-0.21 | $-0.20 | $-0.19 | $-0.27 | $-0.33 | $-0.28 | $-0.45 | $-0.50 | $-0.50 | $-0.45 | $-0.82 | $-1.05 | $-10.54 | $-13.20 | $-15.53 | $-8.04 | $-14.03 | $-1.45 | $-8.28 | $-108.89 | $-60.48 |
Surprise % | - | - | - | - | - | - | - | 0.87% | 0.86% | - | - | 1.07% | 0.89% | - | - | 0.67% | 0.00% | - | - | 0.55% | 13.37% | - | - | 1.25% | 11.42% | 23.67% | 502.06% | 185.87% | 21.57% | - |
Traws Pharma Peer Comparison by Price Target
ONTX Forecast FAQ
Is Traws Pharma a good buy?
Yes, according to 2 Wall Street analysts, Traws Pharma (ONTX) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 2 'Buy' recommendations, accounting for 100.00% of ONTX's total ratings.
What are Traws Pharma's analysts' financial forecasts?
ONTX's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $2.9M (high $2.9M, low $2.9M), average EBITDA is $-2.9M (high $-2.9M, low $-2.9M), average net income is $-20.938M (high $-20.938M, low $-20.938M), average SG&A $92.33M (high $92.33M, low $92.33M), and average EPS is $-0.995 (high $-0.995, low $-0.995).
Did the ONTX's actual financial results beat the analysts' financial forecasts?
Based on Traws Pharma's last annual report (Dec 2023), the company's revenue was $226B, beating the average analysts forecast of $282.83K by 79905710.14%. Apple's EBITDA was $-20.298T, beating the average prediction of $-283K by 7176673060.49%. The company's net income was $-18.948T, beating the average estimation of $-24.27M by 78071429.39%. Apple's SG&A was $9.09T, beating the average forecast of $9M by 100993522.21%. Lastly, the company's EPS was $-0.9, missing the average prediction of $-1.153 by -21.97%. In terms of the last quarterly report (Mar 2023), Traws Pharma's revenue was $56K, missing the average analysts' forecast of $79K by -29.11%. The company's EBITDA was $-6.134M, beating the average prediction of $-79K by 7664.56%. Traws Pharma's net income was $-5.413M, missing the average estimation of $-6.26M by -13.54%. The company's SG&A was $2.11M, missing the average forecast of $2.52M by -15.99%. Lastly, the company's EPS was $-0.26, missing the average prediction of $-0.297 by -12.61%